RIL
AARD

Rothschild Investment LLC’s Aardvark Therapeutics AARD Stock Holding History

Rothschild Investment LLC’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$290 Buy
+77
New +$798 ﹤0.01% 3234

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rothschild Investment LLC's AARD Position: Q1 2026 in Review

Rothschild Investment LLC opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 77 shares worth $290. The stake represents ﹤0.01% of the portfolio and ranks #3234 among its holdings.

79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Rothschild Investment LLC held 77 shares of Aardvark Therapeutics worth $290 as of Q1 2026.
  • Aardvark Therapeutics was a new Rothschild Investment LLC position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3234 holding.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.